Moreover, elevated levels of SLFN5 expression are significantly associated with poor prognosis in ovarian cancer patients, and targeting SLFN5 has been found to inhibit ovarian tumor growth both in vitro and in vivo (60). The gene discussed is SLFN5; the disease is ovarian cancer.